Abstract
Glaucoma drainage devices (GDD) are an invasive procedure for the treatment of glaucoma. The PAUL® Glaucoma Implant (PGI) has been developed as anew, innovative therapeutic procedure. The PGI differs from previous GDD with regard to the smaller size of the drainage tube. This study analyses 6‑months results of the PGI in terms of effectiveness and safety. Adatabase of patients treated with the PGI at the University Eye Hospital Bonn was created and continuously updated based on follow-up controls. Statistical analysis was performed using SPSS Statistics for Windows (IBM Corp., Armonk, NY, USA). Atotal of 53eyes of the first 51consecutive patients treated with the PGI were included in this study. Mean intraocular pressure was 26.62 mmHg (7-48 mmHg) preoperatively and reduced to 12.20 mmHg (3-22 mmHg) after 6months. Local pressure-lowering therapy was reduced from 3.37 agents preoperatively to 0.30 agents after 6months. The complication rate was low; only 3patients (5.8%) had persistent hypotony. In 16patients, the intraluminal prolene stent was removed in the postoperative course after an average of 2.9months. Thereafter, these patients experienced areduction of intraocular pressure from 22.21 to 11.07 mmHg. The PAUL® Glaucoma Implant is asafe treatment modality that can successfully reduce intraocular pressure to alow level and reduce pressure-lowering local therapy. It has alow complication rate, particularly regarding postoperative hypotony.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call